Back to Browse Journals » Eye and Brain » Volume 3

Mitochondrial disorders and the eye

Authors Van Bergen NJ, Chakrabarti R, O’Neill EC, Crowston JG, Trounce IA

Published Date September 2011 Volume 2011:3 Pages 29—47

DOI http://dx.doi.org/10.2147/EB.S16192

Published 27 September 2011

Nicole J Van Bergen, Rahul Chakrabarti, Evelyn C O'Neill, Jonathan G Crowston, Ian A Trounce
Centre for Eye Research Australia, Department of Ophthalmology, University of Melbourne, Victoria, Australia

Abstract: The clinical significance of disturbed mitochondrial function in the eye has emerged since mitochondrial DNA (mtDNA) mutation was described in Leber's hereditary optic neuropathy. The spectrum of mitochondrial dysfunction has become apparent through increased understanding of the contribution of nuclear and somatic mtDNA mutations to mitochondrial dynamics and function. Common ophthalmic manifestations of mitochondrial dysfunction include optic atrophy, pigmentary retinopathy, and ophthalmoplegia. The majority of patients with ocular manifestations of mitochondrial disease also have variable central and peripheral nervous system involvement. Mitochondrial dysfunction has recently been associated with age-related retinal disease including macular degeneration and glaucoma. Therefore, therapeutic targets directed at promoting mitochondrial biogenesis and function offer a potential to both preserve retinal function and attenuate neurodegenerative processes.

Keywords: mitochondria, disease, retina, eye, aging, neuroprotection

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Sensitivity and specificity of the iVue iWellnessExam™ in detecting retinal and optic nerve disorders

Awad C, Slotnick S, Nath S, Sherman J

Eye and Brain 2013, 5:9-21

Published Date: 14 February 2013

Delayed saccadic eye movements in glaucoma

Kanjee R, Yücel YH, Steinbach MJ, González EG, Gupta N

Eye and Brain 2012, 4:63-68

Published Date: 27 November 2012

Update on neuromyelitis optica: natural history and management

Jindahra P, Plant GT

Eye and Brain 2012, 4:27-41

Published Date: 28 March 2012

Neuro-ophthalmic sarcoidosis

Baughman RP, Weiss KL, Golnik KC

Eye and Brain 2012, 4:13-25

Published Date: 14 March 2012

Low-level light therapy of the eye and brain

Rojas JC, Gonzalez-Lima F

Eye and Brain 2011, 3:49-67

Published Date: 17 October 2011

Usefulness of serum mass spectrometry to identify women diagnosed with higher grades of cervical intraepithelial neoplasia may differ by race

Matthews R, Azuero A, Asmellash S, Brewster E, Partridge EE, Piyathilake CJ

International Journal of Women's Health 2011, 3:185-192

Published Date: 12 July 2011

Energy metabolism of the visual system

Margaret Wong-Riley

Eye and Brain 2010, 2:99-116

Published Date: 15 July 2010

Oxybutynin extended release for the management of overactive bladder: a clinical review

AM Arisco, EK Brantly, SR Kraus

Drug Design, Development and Therapy 2009, 3:151-161

Published Date: 26 May 2009